On May 22, 2026, Bernstein initiated coverage of Revolution Medicines (NasdaqGS:RVMD) with a Market Perform recommendation. The average one-year price target for the company is projected at $183.92 per share, suggesting a potential upside of 19.64% from its latest closing price of $153.73 per share.
Projected annual revenue for Revolution Medicines is $118 million, marking an astonishing increase of 15,864.96%. As of the last quarter, 531 funds or institutions hold positions in RVMD, though this represents a decrease of 123 owners (18.81%). Total shares owned by institutions rose by 1.44% to 216,396K shares.
Key shareholders include Farallon Capital Management, with a 6.40% stake, and Janus Henderson Group at 4.59%, both reporting decreases in shares owned. The put/call ratio for RVMD stands at 1.05, indicating a bearish outlook.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
